Avalon GloboCare (NASDAQ:ALBT) Shares Down 5.5% – Here’s What Happened

Avalon GloboCare Corp. (NASDAQ:ALBT) fell 5.5% on Monday . The stock traded as low as $1.3650 and last traded at $1.38. 18,757 shares traded hands during trading, a decline of 50% from the average session volume of 37,630 shares. The stock had previously closed at $1.46.

Analyst Ratings Changes

A number of research firms have recently issued reports on ALBT. Wall Street Zen lowered Avalon GloboCare to a “strong sell” rating in a report on Saturday, September 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Avalon GloboCare in a report on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has an average rating of “Sell”.

Avalon GloboCare Trading Down 5.5%

The firm has a 50-day simple moving average of $1.94 and a two-hundred day simple moving average of $2.40. The company has a market capitalization of $5.87 million, a price-to-earnings ratio of -0.39 and a beta of -0.11.

Avalon GloboCare (NASDAQ:ALBT) last announced its quarterly earnings results on Friday, November 14th. The company reported ($0.06) earnings per share (EPS) for the quarter. The firm had revenue of $0.35 million during the quarter.

Avalon GloboCare Company Profile

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells.